Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
|
|
Kips Bay Medical, Inc. (KIPS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/06/2015 |
8-K
| Quarterly results |
| 05/12/2015 |
8-K
| Quarterly results |
| 11/06/2014 |
8-K
| Quarterly results|
Docs:
|
"Kips Bay Medical Provides Feasibility Study Update and Reports Third Quarter 2014 Results MINNEAPOLIS, MN, November 6, 2014 – Kips Bay Medical, Inc. , a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS ® Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provided a business update and announced financial results for its third quarter ended September 27, 2014. Feasibility Study Update" |
|
| 08/12/2014 |
8-K
| Quarterly results|
Docs:
|
"Kips Bay Medical Provides Feasibility Study Update and Reports Second Quarter 2014 Results MINNEAPOLIS, MN, August 12, 2014 – Kips Bay Medical, Inc. , a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS ® Mesh, for use in coronary artery bypass grafting, or CABG, surgery, today provided a business update and announced financial results for its second quarter ended June 28, 2014. Enrollment Begins at Lenox Hill Hospital in New York" |
|
| 05/08/2014 |
8-K
| Quarterly results |
| 03/12/2014 |
8-K
| Quarterly results |
| 11/07/2013 |
8-K
| Form 8-K - Current report |
| 08/08/2013 |
8-K
| Quarterly results |
| 05/09/2013 |
8-K
| Quarterly results |
| 03/28/2013 |
8-K
| Quarterly results |
| 11/13/2012 |
8-K
| Quarterly results|
Docs:
|
"Kips Bay Medical Provides FDA Update and Reports Third Quarter 2012 Results Minneapolis, MN, November 13, 2012 —Kips Bay Medical, Inc. along with Manny Villafaña, its Founder, Chairman and CEO, provides an FDA update and announces financial results for its third quarter ended September 29, 2012. FDA Update On November 8, 2012, the Company announced that the United States Food and Drug Administration has granted conditional approval of Kips Bay Medical's Investigational Device Exemption to include four U.S. study sites in the “eMESH I” clinical feasibility trial of its eSVS® Mesh. The Company is currently working through the internal review and approval process with a number of leading cardiac centers in the United States. The eMESH I clinical feasibility trial is a multi-center, rando..." |
|
| 08/09/2012 |
8-K
| Quarterly results|
Docs:
|
"Kips Bay Medical Provides FDA Update and Reports Second Quarter 2012 Results Minneapolis, MN, August 9, 2012 —Kips Bay Medical, Inc. today provides an FDA update and announces financial results for its second quarter ended June 30, 2012. FDA Update As previously announced on July 18, 2012, Kips Bay Medical filed an application for an Investigational Device Exemption with the U.S. Food & Drug Administration to include four U.S. sites in the “eMESH I” clinical feasibility study of its innovative eSVS® Mesh device currently being pursued in Europe. As of the date of this press release, a number of leading cardiac centers in the U.S. have already expressed an interest in participating in the eMESH I study, pending FDA approval of the IDE. The eSVS Mesh is a highly flexible, kink-resistant tubu..." |
|
| 03/15/2012 |
8-K
| Form 8-K - Current report |
| 11/08/2011 |
8-K
| Form 8-K - Current report |
| 08/10/2011 |
8-K
| Form 8-K - Current report |
|
|